INT199569

From wiki-pain
Jump to: navigation, search
Context Info
Confidence 0.36
First Reported 2006
Last Reported 2007
Negated 0
Speculated 0
Reported most in Body
Documents 4
Total Number 7
Disease Relevance 3.73
Pain Relevance 0.23

This is a graph with borders and nodes. Maybe there is an Imagemap used so the nodes may be linking to some Pages.

signal transduction (Braf) plasma membrane (Braf) nucleus (Braf)
kinase activity (Braf) cytoplasm (Braf)
Braf (Mus musculus)
Braf - V600E (1)
Pain Link Frequency Relevance Heat
imagery 48 92.00 High High
Central nervous system 12 5.00 Very Low Very Low Very Low
isoflurane 12 5.00 Very Low Very Low Very Low
anesthesia 4 5.00 Very Low Very Low Very Low
palliative 3 5.00 Very Low Very Low Very Low
cytokine 3 5.00 Very Low Very Low Very Low
adenocard 3 5.00 Very Low Very Low Very Low
Kinase C 3 5.00 Very Low Very Low Very Low
Disease Link Frequency Relevance Heat
Skin Cancer 4 99.12 Very High Very High Very High
Melanoma 29 98.72 Very High Very High Very High
Malignant Neoplastic Disease 7 98.36 Very High Very High Very High
Cancer 271 96.96 Very High Very High Very High
Disease Progression 13 96.52 Very High Very High Very High
Renal Cell Carcinoma 150 84.64 Quite High
Brain Tumor 16 74.04 Quite High
Adenocarcinoma 6 45.64 Quite Low
Non-small-cell Lung Cancer 18 37.32 Quite Low
Severe Combined Immunodeficiency 8 36.96 Quite Low

Sentences Mentioned In

Key: Protein Mutation Event Anatomy Negation Speculation Pain term Disease term
Potent inhibition of both BRAF and V600E BRAF was noted with IC50 values between 20–40 nmol/L.
Negative_regulation (inhibition) of BRAF
1) Confidence 0.36 Published 2006 Journal Therapeutics and Clinical Risk Management Section Body Doc Link PMC1661649 Disease Relevance 0.27 Pain Relevance 0
Potent inhibition of both BRAF and V600E BRAF was noted with IC50 values between 20–40 nmol/L.
Negative_regulation (inhibition) of V600E BRAF (V600E)
2) Confidence 0.32 Published 2006 Journal Therapeutics and Clinical Risk Management Section Body Doc Link PMC1661649 Disease Relevance 0.27 Pain Relevance 0
Sorafenib is also known to inhibit the BRAF mutant V600E which is present in over half of malignant melanomas (Davies et al 2002).
Negative_regulation (inhibit) of BRAF associated with melanoma
3) Confidence 0.27 Published 2006 Journal Therapeutics and Clinical Risk Management Section Body Doc Link PMC1661649 Disease Relevance 0.45 Pain Relevance 0
For the study presented in this report, endogenous B-Raf depletion was tracked by engineering a luceriferase-based reporter in which B-raf was cloned downstream of the luciferase stop codon.
Negative_regulation (depletion) of B-Raf
4) Confidence 0.10 Published 2007 Journal BMC Biotechnol Section Body Doc Link PMC2174931 Disease Relevance 0.68 Pain Relevance 0.04
We have since continued to deplete oncogenic B-Raf in multiple settings and now provide additional data to further demonstrate how this technology may be applied.
Negative_regulation (deplete) of B-Raf
5) Confidence 0.10 Published 2007 Journal BMC Biotechnol Section Body Doc Link PMC2174931 Disease Relevance 0.84 Pain Relevance 0.08
We have previously demonstrated the utility of our approach by measuring the effect of oncogenic B-Raf depletion in a mouse model of metastatic melanoma.
Negative_regulation (depletion) of B-Raf associated with melanoma
6) Confidence 0.10 Published 2007 Journal BMC Biotechnol Section Body Doc Link PMC2174931 Disease Relevance 0.43 Pain Relevance 0.05
We also observed an inhibition of B-Raf signaling upon silencing, demonstrated by a decrease in phospho-Erk1/2 levels.
Negative_regulation (inhibition) of B-Raf
7) Confidence 0.10 Published 2007 Journal BMC Biotechnol Section Body Doc Link PMC2174931 Disease Relevance 0.79 Pain Relevance 0.06

General Comments

This test has worked.

Personal tools
Namespaces

Variants
Actions
Navigation
Toolbox